5 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat

4. Emergent Biosolutions Inc. (NYSE:EBS)

Number of Hedge Fund Holders: 17

Emergent BioSolutions Inc. (NYSE:EBS) operates as a life sciences company that focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company offers the ACAM2000 for treating smallpox and vaccinia immune globulin intravenous that addresses complications from its smallpox vaccine. The U.S. is stockpiling monkeypox vaccines and has also reportedly stocked the ACAM2000 which can be used to treat monkeypox.

On May 16, Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into an agreement with Chimerix, Inc. (NASDAQ:CMRX) to acquire the global exclusive rights for the distribution of TEMBEXA. TEMBEXA is the first FDA-approved antiviral drug for the treatment of smallpox in individuals of all ages.

At the close of Q1 2022, 17 hedge funds held stakes in Emergent Biosolutions Inc. (NYSE:EBS). The total value of these stakes amounted to $137.21 million, up from $124.55 million in the previous quarter with 15 positions. The hedge fund sentiment for the stock is positive.

In the first quarter of 2022, D E Shaw raised its stakes in Emergent Biosolutions Inc. (NYSE:EBS) by 24%, bringing them to $47.77 million. As of March 31, D E Shaw is the largest shareholder in Emergent Biosolutions Inc. (NYSE:EBS).